Get the Stockscreener App
8.83
4.54%
-0.42
After Hours:
9.10
0.27
+3.06%
Greenwich Lifesciences Inc stock is traded at $8.83, with a volume of 389.36K.
It is down -4.54% in the last 24 hours and down -26.11% over the past month.
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.
See More
Previous Close:
$9.25
Open:
$9.01
24h Volume:
389.36K
Relative Volume:
8.48
Market Cap:
$116.07M
Revenue:
-
Net Income/Loss:
$-8.89M
P/E Ratio:
-12.61
EPS:
-0.7
Net Cash Flow:
$-6.48M
1W Performance:
-13.60%
1M Performance:
-26.11%
6M Performance:
-35.74%
1Y Performance:
-50.81%
1-Day Range:
$8.29
$9.40
1-Week Range:
$8.29
$10.91
52-Week Range:
$8.29
$18.75
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Name
Greenwich Lifesciences Inc
Sector
Industry
Phone
203-434-3290
Address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
8.83 | 116.07M | 0 | -8.89M | -6.48M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Stock (GLSI) Latest News
Greenwich LifeSciences reports progress on FLAMINGO-01 trial By Investing.com - Investing.com South Africa
GLSI stock touches 52-week low at $9.05 amid market challenges By Investing.com - Investing.com South Africa
Investigative Agent Elicits Responses in Phase 3 Breast Cancer Trial - Curetoday
Greenwich Lifesciences Provides Global Update On Flamingo-01 - MarketScreener
Greenwich LifeSciences Provides Global Update on FLAMINGO-01 - GlobeNewswire
Greenwich LifeSciences reports progress on FLAMINGO-01 trial - Investing.com
Major Breakthrough: Cancer Prevention Trial Reports Positive Data, Elite Hospitals Join - Stock Titan
Flamingo cancer vaccine in phase III pink, Greenwich time nigh? - BioWorld MedTech
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Greenwich LifeSciences stock rises on cancer shot data (GLSI) - Seeking Alpha
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial - The Manila Times
Greenwich Lifesciences Announces Positive Immune Response Data From FLAMINGO-01 Phase III Clinical Trial - MarketScreener
Clinical Trial Success: GLSI's Breast Cancer Therapy Shows Promising Results in Expanded Patient Group - Stock Titan
Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 6.7%Time to Sell? - MarketBeat
Recent 15% decline may not have gone down well with Greenwich LifeSciences, Inc. (NASDAQ:GLSI) insiders who've been purchasing recently - simplywall.st
Greenwich LifeSciences Delays Yearly Report Filing - TipRanks
How To Trade (GLSI) - news.stocktradersdaily.com
Greenwich LifeSciences Extends Lock-Up Period for Directors, Officers to March 2026 - MarketScreener
Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026 - GlobeNewswire
Major Insider Confidence Signal: Greenwich LifeSciences Leadership Locks Shares Until 2026 - Stock Titan
HER2-Positive Breast Cancer Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Roche Pharma AG, Dizal Pharma, Greenwich LifeSciences, Ambrx, Alteogen - Barchart
HER2-Positive Breast Cancer Pipeline 2025: Therapies, MOA - openPR.com
GLSI stock touches 52-week low at $10.52 amid market challenges - Investing.com
Greenwich LifeSciences gets DSMB approval to continue late-stage trial of GLSI-100 - MSN
Greenwich LifeSciences Says Preliminary Safety Data for Breast Cancer Therapy Appears Consistent With Prior Trials - Marketscreener.com
Greenwich LifeSciences reports positive safety data on GLSI-100 - Investing.com India
Greenwich LifeSciences reports positive safety data on GLSI-100 By Investing.com - Investing.com UK
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01 - GlobeNewswire
Greenwich's Breast Cancer Drug Proves Safe in Phase III Trial, Building on 80% Recurrence Reduction - StockTitan
Trading (GLSI) With Integrated Risk Controls - news.stocktradersdaily.com
Non-Small Cell Lung Cancer Clinical Trial Pipeline | 100+ Companies Pioneering the Future of Treatment - openPR
55% of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) is owned by insiders, and they've been buying recently - Yahoo Finance
Learn to Evaluate (GLSI) using the Charts - news.stocktradersdaily.com
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Sees Large Increase in Short Interest - MarketBeat
Short Interest in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Increases By 5.1% - MarketBeat
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Verra Mobility Corporation (NASDAQ: VRRM) - PR Newswire
Pre-market Movers: TNXP, INBS, SMMT, NDRA... - RTTNews
Research Analysts Set Expectations for GLSI FY2024 Earnings - MarketBeat
HC Wainwright Reiterates Buy Rating for Greenwich LifeSciences (NASDAQ:GLSI) - MarketBeat
What is HC Wainwright’s Estimate for GLSI FY2024 Earnings? - Defense World
Greenwich LifeSciences reports progress in FLAMINGO-01 trial - MSN
Greenwich LifeSciences (NASDAQ:GLSI) Given “Buy” Rating at HC Wainwright - Defense World
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) - PR Newswire
Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01 - GlobeNewswire
Greenwich LifeSciences reports progress in FLAMINGO-01 trial By Investing.com - Investing.com UK
Clinical Trial Success: Greenwich's Breast Cancer Immunotherapy Achieves Critical Patient Milestone - StockTitan
Greenwich LifeSciences: Long Time To Results, Little Cash, Hard To Recommend (GLSI) - Seeking Alpha
(GLSI) Technical Pivots with Risk Controls - Stock Traders Daily
EMA approves addition of sites to Greenwich LifeSciences’ breast cancer trial - Yahoo Finance
Greenwich LifeSciences Gets EU Drug Regulator Approval to Add Sites to GLSI-100 Late-Stage Trial - Marketscreener.com
Greenwich LifeSciences stock gains on approval to add additional sites to Flamingo-01 in Europe - MSN
Greenwich Lifesciences Inc Stock (GLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):